Navigation Links
BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Date:12/7/2009

ANNAPOLIS, Md., Dec. 7 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

PharmAthene was informed of BARDA's decision during a meeting late Monday afternoon with BARDA representatives. BARDA issued a press release after the close of the securities markets announcing that it will cancel RFP BARDA 08-15 because it did not believe vaccine developers submitting proposals in response to the request for proposal (RFP) could have product ready for FDA licensure within 8 years. BARDA further announced that instead of re-issuing an RFP, it will request that existing anthrax "vaccine developers submit product development plans under special instructions to an existing broad agency announcement (BAA-BARDA-09-34) that supports the development of medical countermeasures for chemical, biological, radiological and nuclear threats." Dr. Robin Robinson, BARDA Director, stated in the press release, "We believe the broad agency announcement and the flexibilities it provides are well adapted to the further development of these products. Anthrax preparedness remains one of our highest priorities so we will continue to address this threat using all of the authorities and resources at our disposal."

"While we are disappointed by today's news, we remain encouraged by BARDA's continued support for the development of a second generation anthrax vaccine," remarked David P. Wright, President and Chief Executive Officer. "W
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
2. ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
8. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
9. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
10. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
11. Ohio Capital Fund Announces Sponsorship of Minority Business Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... , , MIGDAL HAEMEK, Israel , Feb. ... for modern medicine, as their origins are unclear and the comprehension ... , Applied Spectral Imaging (ASI) a leading provider of ... European Union (EU) to be one out of nine industry and ...
... ... , ... February 16, 2010 -- Akaza Research is pleased to announce its participation in the ... is being held at the Orlando World Center Marriott Resort and is one of ...
... ... for comparison, querying, and sharing of NGS runs; free 2-hour seminar, includes lunch and ... ... Sequencing , , ,Learn about sequence data management and the GenomeQuest interactive, web-based tools ...
Cached Biology Technology:EU Recognizes Importance of ASI's Research on Developing New Smart Imaging Molecular Tools for Combating Neurodegenerative Diseases 2EU Recognizes Importance of ASI's Research on Developing New Smart Imaging Molecular Tools for Combating Neurodegenerative Diseases 3Akaza Research to Present OpenClinica Electronic Data Capture Software at Partnerships in Clinical Trials 2010 2GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing 2
(Date:4/16/2014)... Florida State University researchers have identified a new syndrome ... density and muscle mass with obesity. , "It used ... the better your bones would be because the bones ... Stiebeling Professor of Nutrition at Florida State. "But, that,s ...
(Date:4/16/2014)... known as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) ... muscle weakness and atrophy. Researchers have long considered it to ... cells in the spinal cord and brainstem that control muscle ... April 16, 2014 online issue of Neuron , a ...
(Date:4/16/2014)... do all of our movements, thoughts and feelings ... recent studies have suggested that some of the conversations might ... may be listening in on, or even participating in, some ... astrocytes might only be tuning in part of the time ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3
... College of Medicine have discovered how the mutated huntingtin gene ... Huntington,s disease. The report of their findings is available in ... to show that the mutated huntingtin gene activates a particular ... further, to show what effect activation of that enzyme has ...
... DC - A protein known to play a role ... have a mixed function in breast cancer development, say ... University Medical Center (GUMC). The findings, presented at ... DC, indicate that the function of this protein, known ...
... Sophisticated sensors that measure leaf wetness, soil moisture ... Springbrook World Heritage precinct in south-east Queensland. ... uncover the microclimatic conditions favourable for rapid natural ... of ten sensor nodes, connected wirelessly, has been ...
Cached Biology News:Huntington's disease deciphered 2Huntington's disease deciphered 3Dual role in breast tissue for a protein involved in leukemia 2Rainforest rehab in every sense 2
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
Request Info...
Biology Products: